NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mia T Minen, MD
- Phone Number: 2122637744
- Email: Mia.minen@nyulangone.org
Study Contact Backup
- Name: Erin Waire
- Phone Number: 9294555584
- Email: Erin.waire@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- English speaking. (At this time, the validated app is only available in English.)
- 18-65 years of age
- Meets International Classification of Headache Disorder (ICHD)-3 migraine criteria based on a headache specialist or neurologist
- Headaches for ≥1 year
- Has not begun a new migraine preventative medication in the last month
- Agreement to not make any preventive medication changes from the time of trial start until 3 months after beginning the study (Note - Acute medications may be changed if needed. Changes in preventive and acute medication and the time initiated will be recorded to evaluate the potential for medication confounds)
- 4-29 headache days a month (so the study includes those in whom the investigators typically offer preventive treatment [>4 headache days/month] and those with more frequent migraines including chronic migraine [15 days or more/month] but exclude those with continuous headaches)
Exclusion Criteria:
- Diagnosis of Medication Overuse Headache (MOH)
- Patients who have had Cognitive Behavioral Therapy, Biofeedback, or other Relaxation Therapy for migraine in the past year
- Alcohol or other substance abuse as determined by self-report or prior documentation in the medical record
- Current opioid or barbiturate use
- PHQ-8 scores greater than 15, indicating a conservative score of moderately severe depressive symptoms based on the PHQ-9 (in this group, more intense psychological intervention targeted to the depression may be needed, as depression is a significant predictor of migraine chronification and people with migraine and comorbid depression are more likely to be refractory to migraine treatments and to develop medication overuse headache)
- Unable or unwilling to follow a treatment program that relies on written and audio-taped materials
- Coronary heart disease, heart attack, stroke, diabetes mellitus Type 1 or II
- Pregnant (because hormonal fluctuations in pregnancy can affect migraine outcomes)
- Other physical limitations which would prevent participating in the standard protocol of biofeedback being studied
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: In-Person Migraine Self-Management
|
Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
Participants will receive in-person training in migraine self-management techniques.
|
|
Active Comparator: Remote Migraine Self-Management
|
Participants will receive access to the smartphone application RELAXaHEAD, which contains features for migraine self-management including a headache diary.
Participants will receive virtual training in migraine self-management techniques.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of In-Person Sessions Attended by Participants in the In-Person Migraine Self-Management Arm
Time Frame: Up to Month 2
|
Up to Month 2
|
|
|
Number of Days of At-Home Practice
Time Frame: Up to Month 2
|
Up to Month 2
|
|
|
Satisfaction Scores
Time Frame: Month 2
|
Assessment of satisfaction with the intervention using a Likert scale from 1 to 5 with 1 being strongly disagree, and 5 being strongly agree; the total score is the response; higher scores indicate greater satisfaction with the intervention.
|
Month 2
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mia T Minen, MD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-01149
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.